Stockreport

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies

Arrowhead Pharmaceuticals, Inc.  (ARWR) 
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arrowheadpharma.com/investor-relations
PDF - ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain-bar [Read more]